Objective: Health technology assessmentserves as a multidisciplinary evidence-based decision-making tool, which can provide scientific grounds for healthcare insurance decisions from multiple dimensions. This paper aims to draw on international advanced experience to explore the application pathways, improvement measures of HTA in healthcare security decision-making within China. Methods: This study employs a literature review method to outline the fundamental concepts of HTA, examine the experience of countries such as the United Kingdom, Canada in HTA process construction as well as management, operation systems. It summarizes the current status of HTA applications in China's healthcare security system, identifying, discussing the main challenges currently. Results: Despite continuous maturation in the application of HTA in China, there are still many challenges, room for improvement in the construction, optimization of its system. Issues include the absence of a specialized government-affiliated HTA institution, the need for process optimization in assessments, the lack of technical evaluation standards for diseases or drugs, the non-standardization of price adjustment increments, decrements. Conclusion: In the future, by continuously improving the HTA system, mechanisms, HTA will play a more significant role in optimizing resource allocation, enhancing the quality of medical services, ensuring public health
Key words
health technology assessment /
healthcare security decision-making /
pharmacoeconomics
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 姚嘉奇,周挺,管欣,等.英国NICE卫生技术评估介绍及对我国医保目录动态调整的启示[J].中国循证医学杂志,2018,18(09): 984-989.
[2] 肖月.英国国家卫生与服务优化研究院的卫生技术评估模式与经验分析[J].医学与社会, 2022,35(08):1-8.
[3] 陈英耀,赵琨.卫生技术评估(第2版)[M].北京:人民卫生出版社,2024.
[4] 胡嘉浩,王嘉韵,陈茜,等.卫生技术评估中公平性的评价与思考[J].中国卫生经济,2024,43(01): 11-16.
[5] 方亚.卫生技术评估在健康保险和健康管理中的应用[J].山东大学学报(医学版),2019, 57(08):61-68.
[6] 李小亭,张秋.美国卫生技术评估的发展研究及借鉴[J].企业科技与发展,2018(11):247-248.
[7] 傅卫,赵琨.中国卫生技术评估的发展与挑战[J].卫生经济研究,2019,36(03):3-5.
[8] 赵锐,赵琨.卫生技术评估走好中国特色发展之路[J].中国卫生,2019(10):76-78.
[9] NICE.NICE health technology evaluations: the manual[Z].https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741.
[10] KALTENTHALER E, PAPAIOANNOU D, BOLAND A, et al.The National Institute for Health and Clinical Excellence single technology appraisal process: lessons from the first 4 years[J].Value in health, 2011, 14(8): 1158-1165.
[11] 李佳晋,黄天笑,孙育杰,等.HTA在发达国家医保体系中的发展及对我国的启示[J].中国医疗保险,2024(01):100-110.
[12] ALLEN N, WALKER S R, LIBERTI L, et al.Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study[J].CMAJ open, 2016, 4(4): E674-E678.
[13] 周挺,李洪超,马爱霞,等.加拿大药品统一审评制度及价格管理体系简析[J].中国卫生经济,2018,37(02):94-96.
[14] 王梦骁,邵蓉.加拿大统一药品审评制度的效果评价及启示[J].卫生经济研究,2016(04): 41-44.
[15] Canada's Drug Agency.Canada’s Drug Agency Launches Consultation on Methods Guide[Z].https://www.cda-amc.ca/sites/default/files/MG%20Methods/MG0030-Quantitative-Methods-Manual-Line-Numbered.pdf.
[16] 张秋,刘蔼霞.澳大利亚卫生技术评估及决策转化的分析和借鉴[J].中国药物经济学,2022, 17(06):44-48.
[17] ALLEN N, WALKER S R, LIBERTI L, et al.Health Technology Assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland[J].Value in health, 2017, 20(3): 320-328.
[18] 茅艺伟,陈英耀,唐檬,等.澳大利亚卫生技术评估的应用[J].中国卫生资源,2014,17(06):484-486.
[19] 李小亭,张秋.美国卫生技术评估的发展研究及借鉴[J].企业科技与发展,2018(11):247-248.
[20] 张秋,刘蔼霞,凌凯诺.荷兰卫生技术评估体系分析及对我国的启示[J].中国卫生经济,2022,41(10):93-96.
[21] CHEN J, XU S, GAO J.The mixed effect of China's new health care reform on health insurance coverage and the efficiency of health service utilisation: a longitudinal approach[J].International kournal of environmental research and public health, 2020, 17(5): 1782.
[22] VIERGEVER R F, HENDRIKS T C C.Targeted public funding for health research in the Netherlands[J].Nederlands Tijdschrift Voor Geneeskunde, 2014 (159): A8174.
[23] ENZING J J, KNIES S, BOER B, et al.Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride?[J].Cambridge University Press (CUP), 2021, 16(4): 440-456.
[24] 国家医疗保障局.《2023年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及申报指南的公告[EB/OL].(2024-11-02)[2023-06-29].https://www.gov.cn/zhengce/zhengceku/202306/content_6889132.htm.
[25] 徐菲,唐密,胡善联,等.多准则决策分析应用于卫生决策的假设基础与基本操作[J].中国卫生资源,2020,23(04):332-336.
[26] HAJI A A H, KARNON J.Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models[J].Pharmacoeconomics, 2011, 29(10): 823-825.
[27] 费敏.基于卫生技术评估的新品医用耗材准入流程探索[J].中国医疗设备,2020,35(07):24-28.
[28] 吕兰婷,傅金澜.卫生技术评估在医疗服务价格项目管理中的应用[J].中国医院管理,2022, 42(07):39-42.
[29] 王耀羚,李雪,王文君,等.卫生技术评估在突发公共卫生事件下的作用[J].医学与哲学,2022, 43(11):53-56+81.
